-
Product Insights
New![]()
Centrale Solaire ABP 26 Solar PV Park
Centrale Solaire ABP 26 Solar PV Park is a solar PV project located in Ile-de-France, France. The project is owned and being developed by Centrale Solaire TQ1 SASAU. The project is at the permitting stage. Empower your strategies with our Centrale Solaire ABP 26 Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Company Insights
New![]()
Innovation and Patenting activity of Nordea Bank Abp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Nordea Bank Abp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABP-450 in Migraine
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ABP-450 in MigraineDrug Details:ABP-450 is under development for the treatment of cervical dystonia and as preventive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABP-671 in Hyperuricemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABP-671 in Hyperuricemia Drug Details: ABP-671 is under development for the treatment of gout associated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABP-671 in Gouty Arthritis (Gout)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABP-671 in Gouty Arthritis (Gout) Drug Details: ABP-671 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABP-450 in Spasmodic Torticollis (Cervical Dystonia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ABP-450 in Spasmodic Torticollis (Cervical Dystonia) Drug Details:ABP-450 is under development for the treatment of cervical...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eculizumab Biosimilar in Paroxysmal Nocturnal Hemoglobinuria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Eculizumab Biosimilar in Paroxysmal Nocturnal Hemoglobinuria Drug Details:Eculizumab (Bekemv) is a humanized monoclonal antibody, acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Ulcerative Colitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Ulcerative Colitis Drug Details: ATI-2138 is under development for the treatment of psoriasis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-108 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LM-108 in Solid Tumor Drug Details: LM-108 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TRV-734 in Opium Withdrawal Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TRV-734 in Opium Withdrawal SyndromeDrug Details:TRV-734 is under development for the treatment of opium withdrawal syndrome....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.